These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 30489424)

  • 1. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
    Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
    Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
    Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
    Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
    Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
    Kagan R; Constantine G; Kaunitz AM; Bernick B; Mirkin S
    Menopause; 2018 Dec; 26(6):622-628. PubMed ID: 30586005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
    Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
    Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
    Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
    Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
    [No Abstract]   [Full Text] [Related]  

  • 10. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
    Archer DF; Bernick BA; Mirkin S
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
    [No Abstract]   [Full Text] [Related]  

  • 11. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).
    Mirkin S; Goldstein SR; Archer DF; Pickar JH; Graham S; Bernick B
    Menopause; 2020 Apr; 27(4):410-417. PubMed ID: 31913228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
    Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF
    Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial.
    Caan B; LaCroix AZ; Joffe H; Guthrie KA; Larson JC; Carpenter JS; Cohen LS; Freeman EW; Manson JE; Newton K; Reed S; Rexrode K; Shifren J; Sternfeld B; Ensrud K
    Menopause; 2015 Jun; 22(6):607-15. PubMed ID: 25405571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.
    Woodis CB; Ghassemi E; McLendon AN
    Ann Pharmacother; 2021 Sep; 55(9):1153-1158. PubMed ID: 33345556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms in Europe and China.
    Yu Q; Stevenson JC; Tatarchuk T; Nappi RE; Graziano Custodio M; Kahler E; Simoncini T; Yang J; Ren M
    Climacteric; 2024 Oct; 27(5):494-500. PubMed ID: 39077780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial.
    Diem SJ; Guthrie KA; Mitchell CM; Reed SD; Larson JC; Ensrud KE; LaCroix AZ
    Menopause; 2018 Oct; 25(10):1086-1093. PubMed ID: 29738424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial.
    Liu JH; Black DR; Larkin L; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Dec; 27(12):1388-1395. PubMed ID: 32842052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
    Shulman LP; Yankov V; Uhl K
    Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.